- Home
- ABTS vs GOVX Comparison
ABTS vs GOVX Comparison
Compare ABTS & GOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ABTS | GOVX |
|---|---|---|
| Founded | 2010 | 2001 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2M | 3.8M |
| IPO Year | 2021 | 1996 |
Fundamental Metrics
Financial Performance| Metric | ABTS | GOVX |
|---|---|---|
| Price | $1.40 | $0.64 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $1.00 |
| AVG Volume (30 Days) | 73.0K | ★ 281.4K |
| Earning Date | 04-29-2026 | 04-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,489,145.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.76 | $0.12 |
| 52 Week High | $10.86 | $4.40 |
Technical Indicators
Market Signals| Indicator | ABTS | GOVX |
|---|---|---|
| Relative Strength Index (RSI) | 55.26 | 34.19 |
| Support Level | $0.96 | $0.14 |
| Resistance Level | $1.48 | $0.85 |
| Average True Range (ATR) | 0.21 | 0.07 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 60.29 | 18.38 |
Price Performance
Historical ComparisonAbout ABTS Abits Group Inc
Abits Group Inc is a bitcoin mining company. The Company operates self-owned and hosted bitcoin mining facilities in Tennessee, United States.
About GOVX GeoVax Labs Inc.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. The company is focused on the advancement of GEO-MVA, a Modified Vaccinia Ankara (MVA) vaccine candidate for mpox, smallpox, and other poxviruses. Its flagship clinical program in oncology is Gedeptin, a novel oncolytic solid tumor gene-directed therapy, which recently completed a multicenter Phase 1/2 clinical trial for head and neck cancers. The company is also developing GEO-CM04S1, a next-generation multi-antigen COVID-19 vaccine, which is currently being evaluated in two Phase 2 clinical trials.